STOCK TITAN

Squadron reports 3,676,900-share stake in Zentalis (ZNTL)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Zentalis Pharmaceuticals, Inc. Schedule 13G reports that Squadron Master Fund LP (and related advisor and partners) beneficially hold 3,676,900 shares of common stock, representing 5.1% of the class.

The filing states this percentage is based on 72,250,779 shares outstanding as of November 1, 2025. The reporting persons disclose shared voting and shared dispositive power over the 3,676,900 shares and include a Rule 13d-4 disclaimer of beneficial ownership.

Positive

  • None.

Negative

  • None.

Insights

Holder reports a passive >5% position with shared voting/dispositive power.

The statement identifies Squadron Master Fund LP, its adviser, and two partner-reporting persons as holders of 3,676,900 shares (5.1%), with shared voting and dispositive authority.

This filing cites the 72,250,779 shares outstanding as of November 1, 2025 and includes a Rule 13d-4 disclaimer; subsequent disclosures would be required if the holder’s intent or control changes.

Ownership level exceeds the 5% threshold that triggers Schedule 13G reporting.

The reported 5.1% stake meets the regulatory threshold for beneficial ownership disclosure and shows shared voting/dispositive power rather than sole control, consistent with passive or advisor-led holdings.

Market impact depends on any future amendments or transactions; timing and transaction intent are not stated in the excerpt.






02/24/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Squadron Master Fund LP
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner, Squadron Partners LLC, its General Partner
Date:03/03/2026
Squadron Capital Management LLC
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner
Date:03/03/2026
Matthew Sesterhenn
Signature:/s/ Matthew Sesterhenn
Name/Title:Matthew Sesterhenn
Date:03/03/2026
William Blank
Signature:/s/ William Blank
Name/Title:William Blank
Date:03/03/2026

FAQ

What stake does Squadron Master Fund report in ZNTL?

The filing reports 3,676,900 shares, representing 5.1% of common stock. This percentage is calculated using 72,250,779 shares outstanding as of November 1, 2025, as cited in the statement.

Who is listed as the beneficial owner of the shares in the ZNTL filing?

The filing lists Squadron Master Fund LP, Squadron Capital Management, LLC, and partners Matthew Sesterhenn and William Blank as reporting persons for the same 3,676,900 shares position.

What voting and dispositive powers are reported for the ZNTL shares?

The reporting persons disclose 0 sole voting and 3,676,900 shared voting power, and 0 sole dispositive and 3,676,900 shared dispositive power over the reported shares.

Does the Schedule 13G state the reporting persons claim beneficial ownership?

The filing includes a Rule 13d-4 disclaimer in which Squadron Capital Management, LLC and the partners expressly disclaim beneficial ownership, while reporting their shared power over the 3,676,900 shares.

How was the percent of class calculated in the ZNTL filing?

The percent is based on the issuer’s reported 72,250,779 shares outstanding as of November 1, 2025, per the filing; the reported position equals 5.1% of that total.
Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

View ZNTL Stock Overview

ZNTL Rankings

ZNTL Latest News

ZNTL Latest SEC Filings

ZNTL Stock Data

191.66M
55.71M
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO